Search

Copyright of Der Nephrologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

About an Indirect Proof of Ovulation and Ovafertilisation in Dogs by Continued Controls of Plasma Progesterone Levels: In addition to already published data (A rbeiter et al., 1990) we could achieve important facts concerning the estimation of mating time of the bitch by measuring the progesterone (P4) level continuously and observing the clinical signs on a collective of 106 ambulant patients. We found that a P 4-concentration of 5 ng/ml plasma and above is signalizing ovulation or ovafertilisation; a sudden rise of the progesterone over 10 ng (Ovucheck®), reflecting 19.2 ng/ml (Serozyme®-Progesterone), turned out to be a diagnostic mark for determination of mating time. Copulation took place between the 9th and 19th day of heat. 89% of the controllable bitches (n = 79) conceived and birth occurred 61.4 days (x̄) later. The litter size and the loss of dead born puppies (4.7 %) was normal with regard to the pertinent races. Because of their easy handling the P 4-testkits (Ovucheck®; Serozyme®-Progesterone) are of good use for the practician. Zusammenfassung Bereits publizierte Untersuchungen weiterführend (A rbeiter u. Mitarb., 1990), konnten an 106 ambulant betreuten Patienten aufgrund von Progesteron-Verlaufskontrollen im Verein mit den klinischen Befunden wesentliche Erkenntnisse für eine präzisere Bestimmung der Deckzeit bei der Hündin gewonnen werden. Es wurde ermittelt, daß ein P4-Gehalt von 5 ng/ml Plasma und darüber die Freisetzung und nachfolgende Fertilisation der Ova anzeigt und das sprunghafte Ansteigen auf > 10 ng/ml (Ovucheck®) entsprechend 19,2 ng/ml (Serozyme®-Progesteron), ein diagnostischer Richtwert für die Deckzeitbestimmung ist. Die Belegungen erfolgten zwischen dem 9. und 19. Tag der Läufigkeit; 89% der kontrollierbaren Hündinnen (n = 79) konzipierten und kamen nach 61,4 Tagen (x̄) zur Geburt. Die Wurfgrößen waren den Rassen gemäß, der Verlust an Totgeburten (4,7%) der Norm entsprechend. - Die einfach auszuführenden P4-Messungen (Ovucheck®-Schätzwerte; Serozyme®-Progesteron-Digitalmessung) machen die Verfahren auch für die Praxis geeignet. [ABSTRACT FROM AUTHOR]

Possibilities of Initiation of Oestrus in the Bitch with an Ergolin Derivative To initiate oestrus in the bitch has medical indications (anoestrus, suboestrus) as well as breeding motives (shortening the intervals between oestrus, birth control). 23 bitches were treated with the new Ergoline-derivate FCE 21336. Most of the patients were presented because of an extended interval of heat. FCE 21336 operates by prolactin inhibition. An average treatment started 8.5 months after the last heat and lasted for a period of 7 days (dosing once per day per os). Within 12 days after the first dose all bitches were in heat. 12 of the 14 bitches served conceived about 10 days after dosing. Eleven have produced litters; information about one is not available. Zusammenfassung Die Induktion der Läufigkeit (LFK) kann bei der Hündin sowohl medizinisch (An-, Suböstrie) als auch züchterisch (Verkürzung des LFK-Intervalls, Geburtenplanung) indiziert sein. Wir haben 23 Hündinnen, die vorwiegend wegen eines verlängerten LFK-Intervalls vorgestellt wurden, mit dem neuen Ergolin-Derivat FCE 21336 behandelt. FCE 21336 wirkt als Prolactin-Inhibitor. Die Medikation erfolgte im Durchschnitt 8,5 Monate nach der letzten LFK über 7 Tage (Verabreichung 1 × tgl. per os). Alle Hündinnen wurden im Mittel 7,2 Tage nach der Erstbehandlung läufig. Von den 14 um den 10. Tag p.m. belegten Tieren konzipierten 12 (85,7%), 11 (78%) haben nachweislich geboren; die Daten einer Hündin sind ausständig. [ABSTRACT FROM AUTHOR]

Abstract Background Peritoneal dialysis (PD) is the preferred dialysis modality in children. Its major drawback is the limited technique survival due to infections and progressive ultrafiltration failure. Conventional PD solutions exert marked acute and chronic toxicity to local tissues. Prolonged exposure is associated with severe histopathological alterations including vasculopathy, neoangiogenesis, submesothelial fibrosis and a gradual loss of the mesothelial cell layer. Recently, more biocompatible PD solutions containing reduced amounts of toxic glucose degradation products (GDPs) and buffered at neutral pH have been introduced into clinical practice. These solutions contain lactate, bicarbonate or a combination of both as buffer substance. Increasing evidence from clinical trials in adults and children suggests that the new PD fluids may allow for better long-term preservation of peritoneal morphology and function. However, the relative importance of the buffer in neutral-pH, low-GDP fluids is still unclear. In vitro, lactate is cytotoxic and vasoactive at the concentrations used in PD fluids. The BIOKID trial is designed to clarify the clinical significance of the buffer choice in biocompatible PD fluids. Methods/design The objective of the study is to test the hypothesis that bicarbonate based PD solutions may allow for a better preservation of peritoneal transport characteristics in children than solutions containing lactate buffer. Secondary objectives are to assess any impact of the buffer system on acid-base status, peritoneal tissue integrity and the incidence and severity of peritonitis. After a run-in period of 2 months during which a targeted cohort of 60 patients is treated with a conventional, lactate buffered, acidic, GDP containing PD fluid, patients will be stratified according to residual renal function and type of phosphate binding medication and randomized to receive either the lactate-containing Balance solution or the bicarbonate-buffered Bicavera® solution for a period of 10 months. Patients will be monitored by monthly physical and laboratory examinations. Peritoneal equilibration tests, 24-h dialysate and urine collections will be performed 4 times. Peritoneal biopsies will be obtained on occasion of intraabdominal surgery. Changes in small solute transport rates, markers of peritoneal tissue turnover in the effluent, acid-base status and peritonitis rates and severity will be analyzed.